Protecting Medicaid for People with Lung Cancer
“When Wynn first went to the hospital for a collapsed lung, she didn’t have health insurance and believed that she did not get the care she needed. Doctors did an x-ray and dealt with the immediate problem, but did not order additional diagnostic tests to investigate the cause of the collapsed lung. “I felt that because I didn’t have insurance, the hospital did not do a thorough check,” said Wynn.”
Lung cancer survivor, advocate encourage Coloradans to conduct radon testing
“Heidi Nafman-Onda, a lung cancer survivor, and Dr. Pierre Onda are using National Radon Action Month to warn of the dangers of radon and what you can do to protect yourself.”
The Power of Unity: Why the Lung Cancer Genetics Study Matters
“Key Takeaways: The Lung Cancer Genetics Study aims to identify genetic variations linked to lung cancer, enhancing risk assessments and treatment strategies. Collaboration between 23andMe and lung cancer advocates emphasizes patient-centered research, uniting diverse stakeholders for a common goal.”
Intercostal Nerve Cryoablation During Lobectomy for Lung Cancer Is Safe, Cost-Effective
“Intercostal nerve cryoablation during lobectomy for lung cancer is a safe and cost-effective therapy that significantly reduces hospital length of stay, hospital costs, and postoperative opioid use, according to study results published in Pain Therapy.”
New copper detection tool may lead to lung cancer treatment breakthrough
“The Chang Lab at Princeton Chemistry continues in its mission to elucidate the role of metal nutrients in human biology: last year, iron; this year, copper. The lab’s first paper of 2025 showcases its development of a revelatory sensing probe for the detection of copper in human cells and then wields it to uncover how copper may be regulating cell growth in lung cancer.”
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
“AUSTIN, Texas, Jan. 23, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the Company’s Acclaim-3 clinical study of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC).”
Factors associated with lung cancer among firefighters: a systematic literature review
“This short review addresses the pressing issue of lung cancer among firefighters, a population facing unique occupational hazards such as smoke inhalation and asbestos exposure. With lung cancer being a leading global cause of death, the study emphasizes the disproportionate burden on firefighters.”
Local Consolidative Therapy Combo May Extend Survival in Stage IV NSCLC
“Local consolidative therapy (LCT) in combination with systemic chemotherapy may extend survival and achieve local control in a small cohort of patients with stage IV non–small cell lung carcinoma (NSCLC) with oligometastases for whom chemoradiotherapy (CRT) for thoracic disease was feasible, according to findings from a single-arm phase 2 study (UMIN000022431) published in Radiation Oncology.”
Trilaciclib May Help Protect Against Chemotherapy Damage in Small Cell Lung Cancer
“Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which authors say minimizes the need for supportive care.”
Getting a Lung Cancer Diagnosis Was Shocking
“I have never smoked, and, as a physician, I’ve always looked after my health. I didn’t realize that my Asian heritage put me at a higher risk for the disease.”
ZL-1310 Receives Orphan Drug Designation in Small Cell Lung Cancer
“ZL-1310, a first-in-class DLL3 antibody-drug conjugate, has been granted orphan drug designation by the FDA for the treatment of patients with small cell lung cancer (SCLC), according to a press release from the developer, Zai Lab.”
miR-224 activates cancer-associated fibroblasts to enhance lung cancer cell migration and invasion by targeting Akirin1
“Cancer-associated fibroblasts (CAFs) actively contribute to the formation of tumor-supportive microenvironments, thereby promoting cancer progression and impacting therapeutic outcomes. This study utilized global microRNA (miRNA) expression profiling to identify specific miRNAs responsible for reprogramming normal lung fibroblasts (LFs) into CAFs. miR-224 demonstrates increased expression in CAFs, and its levels are elevated in lung tumors compared to those in normal tissues, according to data from public databases.”
